HAVCR2 and neoplasm: Sakuishi et al. demonstrated in 2010 that combination therapy of anti-TIM-3 antibody and anti-PD-1 ligand 1 (PD-L1) antibody in mice reduces CT26 colorectal carcinoma tumor size and increases IFN-γ+ tumor-infiltrating lymphocytes (TILs) [93].